P/E ratio for Insmed (INSM)
P/E ratio as of May 2024 (TTM): -4.86
According to Insmed's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.85579. At the end of 2022 the company had a P/E ratio of -5.12.
P/E ratio history for Insmed from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -5.12 | -27.22% |
| 2021 | -7.04 | -36.36% |
| 2020 | -11.1 | 40.79% |
| 2019 | -7.86 | 152.66% |
| 2018 | -3.11 | -71.48% |
| 2017 | -10.9 | 134.03% |
| 2016 | -4.66 | -47.9% |
| 2015 | -8.94 | 6.92% |
| 2014 | -8.36 | -22.28% |
| 2013 | -10.8 | 152.5% |
| 2012 | -4.26 | 309.35% |
| 2011 | -1.04 | -91.9% |
| 2010 | -12.9 | -1704.64% |
| 2009 | 0.8012 | -121.82% |
| 2008 | -3.67 | -24.79% |
| 2007 | -4.88 | 232.89% |
| 2006 | -1.47 | -35.83% |
| 2005 | -2.29 | -29.35% |
| 2004 | -3.24 | -68.41% |
| 2003 | -10.2 | 2460.34% |
| 2002 | -0.4000 | -88.17% |
| 2001 | -3.38 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 26.1 | -636.87% | 🇨🇭 Switzerland |
 Gilead Sciences GILD | 14.9 | -407.32% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | 30.7 | -732.67% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | -16.7 | 244.29% | 🇺🇸 USA |
 Aerie Pharmaceuticals AERI | -20.3 | 318.74% | 🇺🇸 USA |
 Array Technologies ARRY | 24.4 | -603.14% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.